Journal article
The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia
Abstract
OBJECTIVE Epidemiologic studies linking insulin glargine and glucose-lowering therapies to cancers and n-3 fatty acids to cancer prevention have not been confirmed. We aimed to assess the effect of insulin glargine and n-3 fatty acids on incident cancers within the context of the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial. RESEARCH DESIGN AND METHODS The ORIGIN trial is an international, long-term, randomized two-by-two …
Authors
Bordeleau L; Yakubovich N; Dagenais GR; Rosenstock J; Probstfield J; Yu PC; Ryden LE; Pirags V; Spinas GA; Birkeland KI
Journal
Diabetes Care, Vol. 37, No. 5, pp. 1360–1366
Publisher
American Diabetes Association
Publication Date
May 1, 2014
DOI
10.2337/dc13-1468
ISSN
0149-5992